Recently，Clinical trial of medicineAccording to the official website of the registration and information disclosure platform,Haisco is registered.Two itemsHSK44459'sPhase III clinical trial, targeting respectivelyProgressive pulmonary fibrosis (PPF)、Idiopathic pulmonary fibrosis (IPF)。

Source of image:Clinical trial of medicineOfficial website of verification registration and information disclosure platform

HSK44459 is a highly selective PDE4B inhibitor independently developed by Hisico. It exerts dual anti-inflammatory and anti-fibrotic effects by inhibiting the secretion of inflammatory factors and the activation of fibroblast proliferation.